JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB283026

Human MAVS knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

MAVS KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 101 bp deletion in exon 5.

View Alternative Names

CARD adapter inducing interferon beta, CARD adaptor inducing IFN beta, Cardif, DKFZp666M015, FLJ27482, FLJ41962, IFN B promoter stimulator 1, Interferon beta promoter stimulator protein 1, KIAA1271, MAVS_HUMAN, Mitochondrial Antiviral Signaling, Mitochondrial antiviral-signaling protein, Putative NF-kappa-B-activating protein 031N, VISA, Virus-induced-signaling adapter, virus induced signaling adaptor

3 Images
Western blot - Human MAVS knockout A549 cell lysate (AB283026)
  • WB

Lab

Western blot - Human MAVS knockout A549 cell lysate (AB283026)

False colour image of Western blot : Anti-MAVS antibody [abM28C8] staining at 2 ug/ml shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution shown in red. In Western blot ab220170 was shown to bind specifically to MAVS. A band was observed at 70 kDa in wild-type A549 cell lysates with no signal observed at this size in Mavs knockout cell line ab282354 (knockout cell lysate ab283026). To generate this image wild-type and Mavs knockout A549 cell lysates were analysed. First samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5% milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°. Blots were washed four times in TBS-T incubated with secondary antibodies for 1 h at room temperature washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) at 1/20000 dilution.

All lanes:

Western blot - Anti-MAVS antibody [ABM28C8] (<a href='/en-us/products/primary-antibodies/mavs-antibody-abm28c8-ab220170'>ab220170</a>) at 2 µg/mL

Lane 1:

Wild-type A549 cell lysate at 20 µg

Lane 2:

Mavs knockout A549 cell lysate at 20 µg

Lane 2:

Western blot - Human MAVS knockout A549 cell line (<a href='/en-us/products/cell-lines/human-mavs-knockout-a549-cell-line-ab282354'>ab282354</a>)

Lane 2:

Western blot - Human MAVS knockout A549 cell lysate (ab283026)

Predicted band size: 57 kDa

Observed band size: 70 kDa

false

Western blot - Human MAVS knockout A549 cell lysate (AB283026)
  • WB

Lab

Western blot - Human MAVS knockout A549 cell lysate (AB283026)

False colour image of Western blot : Anti-MAVS antibody [ABM28C8] staining at 2 ug/ml, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab220170 was shown to bind specifically to MAVS. A band was observed at 70 kDa in wild-type A549 cell lysates with no signal observed at this size in Mavs knockout cell line ab282354 (knockout cell lysate ab283026). To generate this image, wild-type and Mavs knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5 % milk in TBS-0.1% Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) at 1/20000 dilution.

false

Sanger Sequencing - Human MAVS knockout A549 cell lysate (AB283026)
  • Sanger seq

Supplier Data

Sanger Sequencing - Human MAVS knockout A549 cell lysate (AB283026)

101 bp deletion in exon 5

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 101 bp deletion in exon 5

Disease

Carcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab283026-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human MAVS knockout A549 cell lysate", "number":"AB283026-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB283026-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
MAVS
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

MAVS also known as mitochondrial antiviral-signaling protein is a critical adaptor protein involved in the innate immune response to viral infections. This protein with a molecular weight of approximately 56 kDa is expressed on the mitochondrial membrane. It plays a major role in antiviral defense by transmitting signals from cytosolic pattern recognition receptors like RIG-I-like receptors to initiate downstream immune responses. MAVS can also be referred to as IPS-1 VISA or CARDIF in scientific literature.
Biological function summary

The MAVS protein activates important signaling cascades to produce type I interferons and other cytokines which are essential in the antiviral response. MAVS forms a complex with other proteins on the mitochondrial membrane helping to coordinate a rapid immune reaction to viral pathogens. It acts by amplifying the signal from RIG-I and MDA5 facilitating their role in the recognition of viral RNA. By recruiting downstream signaling molecules MAVS enables the activation of transcription factors like IRF3 and NF-kB.

Pathways

MAVS plays a central role in the signaling pathways that regulate innate immunity including the RIG-I-like receptor signaling pathway and the NF-kB pathway. It interacts with various proteins such as TRIF and STING in the pathways to modulate immune responses. These pathways help trigger the production of antiviral substances and maintain homeostasis within the body's defense mechanisms. MAVS provides a platform for the assembly of signaling complexes which are necessary for the propagation and amplification of the immune response signal.

MAVS is associated with conditions such as viral infections and autoimmune diseases. Dysregulation of MAVS activity has been linked to systemic lupus erythematosus where abnormal immune signaling may occur. MAVS also has connections with other proteins such as TRAF3 and TRAF6 which contribute to disease pathogenesis. Understanding the role of MAVS in these conditions may provide insights into therapeutic targets for improving disease outcomes.

Quality control

STR analysis

D13S317, D7S820, D5S818, TH01, D16S539, TPOX, CSF1PO

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com